Novartis India Limited (BOM:500672)
India
· Delayed Price · Currency is INR | Market Cap | 26.00B |
| Revenue (ttm) | 3.48B |
| Net Income (ttm) | 972.30M |
| Shares Out | 24.69M |
| EPS (ttm) | 39.38 |
| PE Ratio | 26.74 |
| Forward PE | n/a |
| Dividend | 25.00 (2.55%) |
| Ex-Dividend Date | Jul 23, 2025 |
| Volume | 10,974 |
| Average Volume | 14,239 |
| Open | 984.30 |
| Previous Close | 979.45 |
| Day's Range | 984.30 - 1,057.00 |
| 52-Week Range | 747.60 - 1,099.90 |
| Beta | -0.05 |
| RSI | 67.07 |
| Earnings Date | Jan 28, 2026 |
About Novartis India
Novartis India Limited is involved in the pharmaceutical business in India. The company offers therapeutic products in the areas of bone and pain products under the Voveran brand; transplantation immunology products under the Simulect, Certican, Sandimmun, Neoral, and Myfortic brands. It also offers neuroscience products under the Tegrital and Exelon brands. Novartis India Limited was incorporated in 1947 and is headquartered in Mumbai, India. Novartis India Limited operates as a subsidiary of Novartis AG. [Read more]
Financial Performance
In fiscal year 2025, Novartis India's revenue was 3.56 billion, an increase of 6.33% compared to the previous year's 3.35 billion. Earnings were 1.01 billion, an increase of 18.44%.
Financial StatementsNews
Pharma sector stocks today, Feb 20: Novartis India rally 20%, Biocon jumps 1.36%, Alembic rises 1.11%
The Indian pharmaceutical sector showed mixed performance on February 20, 2026, during early trading hours. The S&P BSE Healthcare Index...
Novartis India shares in focus today as mandatory open offer triggered after 70.68% stake deal
Friday, February 20: Shares of Novartis India Limited remain in focus after WaveRise Investments Limited and its consortium partners announced...
Novartis India shares surge 14.65% today after Novartis AG to sell 70.68% stake
Friday, February 20: Shares of Novartis India Limited jumped sharply in early trade after its promoter, Novartis AG, agreed to...
Novartis India stock surges 9% as Alkem Labs eyes ₹2,000 crore acquisition
Novartis India (BSE: ₹1,181.70) surged 8.95% in intraday trading at 3:02 PM, following reports by CNBC-TV18 indicating that Alkem Labs is in talks to acquire the company from its Swiss parent, Novarti...